Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
You may also be interested in...
Latest Big Rounds Herald A China Biotech Funding Spring?
Around the turn of the year, four Chinese biotechs including Kelun Biotech and BioRay ramped up funding with deals worth more than $100m, at a time when overall investment sentiment in the sector remains gloomy.
Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.